Gosset Ownership
Private
Therapeutic Areas
Stage
Phase 1
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Modalities
Ariceum Therapeutics General Information
The company has received FDA clearance for its IND application to commence a Phase I/II clinical trial ('SANTANA-225') of its proprietary radiolabelled peptide, 225Ac-SSO110, in patients with small cell lung cancer (SCLC) or Merkel Cell Carcinoma (MCC). The company also has a radiolabelled PARP-inhibitor (ATT001) currently in Phase 1 clinical development under the trial name CITADEL-123[4][9].
Contact Information
Primary Industry
Biotech
Corporate Office
Berlin, Berlin
Germany
Germany
Drug Pipeline
satoreotide
Phase 1Key Partnerships
ITM Isotope Technologies Munich SE, NorthStar Medical Radioisotopes, Eckert & Ziegler, UCB Pharma
Ariceum Therapeutics Funding
No funding data available
To view Ariceum Therapeutics's complete valuation and funding history, request access »